Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison

INTRODUCTION: Tafasitamab plus lenalidomide (TAFA + LEN) received accelerated US Food and Drug Administration approval and conditional European Medicines Agency approval for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordoba, Raul, Prawitz, Thibaud, Westley, Tracy, Sharma, Anuj, Ambarkhane, Sumeet, Kapetanakis, Venediktos, Sabatelli, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122850/
https://www.ncbi.nlm.nih.gov/pubmed/35403948
http://dx.doi.org/10.1007/s12325-022-02094-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122850/
https://www.ncbi.nlm.nih.gov/pubmed/35403948
http://dx.doi.org/10.1007/s12325-022-02094-5

Ejemplares similares